Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $6.19 and traded as high as $9.45. DBV Technologies shares last traded at $9.01, with a volume of 47,375 shares trading hands.
Analysts Set New Price Targets
A number of research analysts have recently commented on DBVT shares. StockNews.com assumed coverage on shares of DBV Technologies in a research report on Thursday. They set a "hold" rating for the company. JMP Securities upped their target price on shares of DBV Technologies from $10.00 to $15.00 and gave the stock a "market outperform" rating in a report on Thursday.
View Our Latest Research Report on DBV Technologies
DBV Technologies Trading Down 4.4 %
The firm's 50 day simple moving average is $6.28 and its 200-day simple moving average is $4.62. The stock has a market capitalization of $235.83 million, a price-to-earnings ratio of -1.91 and a beta of -0.08.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings data on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. The company had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. As a group, equities research analysts predict that DBV Technologies S.A. will post -7.05 earnings per share for the current year.
Institutional Investors Weigh In On DBV Technologies
A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors own 71.74% of the company's stock.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
